2ER26-1. Addition of 7-Hydroxymitragynine - (methyl (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate); 9-Hydroxycorynantheidine (9-O-Demethylmitragynine, 8-OH) - methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-hydroxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate; 10-Hydroxycorynantheidine ((20S)-10-hydroxycorynantheidine, 10-OH) - Methyl (E)-2-[(2S,3S,12bS)-3-ethyl-9-hydroxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate; Mitragynine pseudoindoxyl - Methyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2, 1'-3, 5, 6, 7, 8, 8a-hexahydro-2H-indolizine, -7'-yl]-3-methoxyprop-2-enoate; 7-Acetoxymitragynine - Methyl (E)-2-[(2S,3S,7aS,12bS)-7a-acetyloxy-3-ethyl-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2, 3-a] quinolizin-2-yl]-3-methoxyprop-2-enoate; Dihydro-7-hydroxymitragynine (MGM-15) - (E)-methyl 2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate; and 9-Fluoro-7-hydroxymitragynine (MGM-16) - (E)-methyl 2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate; TO SCHEDULE I, SUBSECTION 893.03(1)(a), F.S

(1) Under the authority of Section 893.035, F.S., the following substances are hereby controlled substances, added to Schedule I, subsection 893.03(1)(a), F,S.: (a) 7-Hydroxymitragynine - (methyl (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate); (b) 9-Hydroxycorynantheidine (9-O-Demethylmitragynine, 8-OH) - methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-hydroxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate; (c) 10-Hydroxymitragynine ((20S)-10-hydroxycorynantheidine, 10-OH) - Methyl (E)-2-[(2S,3S,12bS)-3-ethyl-10-hydroxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate; (d) Mitragynine pseudoindoxyl - Methyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2, 1'-3, 5, 6, 7, 8, 8a-hexahydro-2H-indolizine, -7'-yl]-3-methoxyprop-2-enoate; (e) 7-acetoxymitragynine - Methyl (E)-2-[(2S,3S,7aS,12bS)-7a-acetyloxy-3-ethyl-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2, 3-a] quinolizin-2-yl]-3-methoxyprop-2-enoate; (f) Dihydro-7-hydroxymitragynine (MGM-15)- (E)-methyl 2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate; and (g) 9-Fluoro-7-hydroxymitragynine (MGM-16)- (E)-methyl 2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate; such that (2) No product shall have 7-hydroxymitragynine, mitragynine pseudoindoxyl, 7-acetoxymitragynine, 9-hydroxycorynantheidine, 10-hydroxymitragynine, dihydro-7-hydroxymitragynine, and 9-Fluoro-7-hydroxymitragynine, or any combination thereof greater than: (a) 1 milligram per gram (mg/g) for solid or powdered products, including encapsulated materials; or (b) 1 milligram per milliliter (mg/mL) for liquid products, including beverages, extracts, and tinctures; and (3) Any product containing 7-hydroxymitragynine, mitragynine pseudoindoxyl, 7-acetoxymitragynine, 9-hydroxycorynantheidine, 10-hydroxymitragynine, dihydro-7-hydroxymitragynine, and 9-Fluoro-7-hydroxymitragynine (or any combination thereof) must have at least 100 parts mitragynine for every one part of 7-hydroxymitragynine (including mitragynine pseudoindoxyl, 7-acetoxymitragynine, 9-hydroxycorynantheidine, 10-hydroxymitragynine, dihydro-7-hydroxymitragynine, and 9-Fluoro-7-hydroxymitragynine) by mass. (4) All provisions of Chapter 893, F.S., applicable to controlled substances listed in Schedule I shall be applicable to the substances listed in subsection (1) above.